Local interleukin 2 therapy is most effective against cancer when injected intratumourally

Cancer Immunology, Immunotherapy

Volumn 54, Issue 7, 2005, Pages 647-654

  Jacobs, John J L ^a,b   Sparendam, Derek ^b   Den Otter, Willem ^a  

^a Faculty of Veterinary Medicine   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anticancer therapy; Interleukin 2; Intratumoural; Mechanism; Vascular leakage

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CELL INFILTRATION; CELL SIZE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CYTOTOXICITY; DRUG EFFICACY; EDEMA; ERYTHROCYTE; FEMALE; INJECTION SITE; LEUKOCYTE; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; FEMALE; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-2; LYMPHOMA; MICE; MICE, INBRED DBA; SURVIVAL RATE;

EID: 21244457998     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0627-4     Document Type: Article

References (40)

1. Angiolillo AL, Kanegane H, Sgadari C, Reaman GH, Tosato G (1997) Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun 223:231
2. Baluna R, Rizo J, Gordon BE, Ghetie V, Vitetta ES (1999) Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. Proc Nat Acad Sci USA 96:3957
3. Baselmans AH, Koten JW, Battermann JJ, Van Dijk JE, Den Otter W (2002) The mechanism of regression of solid SL2 lymphosarcoma after local IL-2 therapy. Cancer Immunol Immunother 51:492
4. Bernsen MR, Tang JW, Everse LA, Koten JW, Den Otter W (1999) Interleukin 2 (IL-2) therapy: potential advantages of locoregional versus systemic administration. Cancer Treat Rev 25:73
5. Bonhomme-Faivre L, Depraetere P, Savelli MP, Amdidouche D, Bizi E, Seiller M, Orbach-Arbouys S (2000) Charcoal suspension for tumour labeling modifies macrophage activity in mice. Life Sci 66:817
6. Bubenik J, Indrova M, Toulcova A (1986) Immunotherapy of murine sarcomas with interleukin 2. I. Local administration of human recombinant IL-2 preparations. Folia Biol (Praha) 32:384
7. Carlos TM (2001) Leukocyte recruitment at sites of tumour: dissonant orchestration. J Leukoc Biol 70:171
8. Characiejus D, Dullens HFJ, Den Otter W (1990) Mechanisms of tumour rejection in the murine DBA/2-SL2 concomitant immunity system. Cancer Immunol Immunother 32:179
9. De Mik HJ, Koten JW, Maas RA, Dullens HF, Den Otter W (1991) Tumour regression by IL-2 mediated stagnation of blood flow. In Vivo 5:679
10. Den Otter W, Dobrowolski Z, Bugajski A, Papla B, Van Der Meijden APM, Koten JW, Boon TA, Siedlar M, Zembala M (1998) Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 159:1183
11. Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg PA, De Mulder PHM, Rhode C, Stewart R, Faber JA, Ruitenberg EJ, Rutten VPMG (1995) Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up. Cancer Immunol Immunother 41:10
12. Den Otter W, Hill FWG, Klein WR, Koten JW, Steerenberg PA, De Mulder PHM, Rutten VPMG, Ruitenberg EJ (1993) Low doses of interleukin-2 can cure large bovine ocular squamous cell carcinoma. Anticancer Res 13:2453
13. Edwards M, Schuschke D, Abney D, Miller F (1991) Interleukin-2 acutely induces protein leakage from the microcirculation. J Surg Res 50:609
14. Harada Y, Yahara I (1993) Pathogenesis of toxicity with human-derived interleukin-2 in experimental animals. Int Rev Exp Pathol 34:37
15. Hill FWG, Klein WR, Hoyer MJ, Rutten VPMG, Kock N, Koten JW, Steerenberg PA, Ruitenberg EJ, Den Otter W (1994) Antitumor effect of locally injected low doses of recombinant human interleukin-2 in bovine vulval papilloma and carcinoma. Vet Immunol Immunopathol 41:19
16. Huland E, Heinzer H, Huland H, Yung R (2000) Overview of interleukin-2 inhalation therapy. Cancer J Sci Am 6(Suppl 1):104
17. Huland E, Huland H, Heinzer H (1992) Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma. J Urol 147:344
18. + T cells that mediate destruction of tumour cells and tumour-associated vasculature: a novel mechanism for IL-2. J Immunol 171:5051
19. Jacobs JJL, Lehé C, Cammans KDA, Das PK, Elliott GR (2000) Methyl green-pyronine staining of porcine organotypic skin explant cultures: an alternative model for screening skin irritants. ATLA 28:279
20. Jacobs JJL, Lehé C, Cammans KDA, Das PK, Elliott GR (2000) Screening of skin irritant by RNA detection as a viability marker in porcine organotypic skin explants. In: Progress in the reduction refinement replacement of animal experimentation, vol 31A, pp 601
21. Jacobs JJL, Lehé C, Cammans KDA, Das PK, Elliott GR (2002) An in vitro model for detecting skin irritants: methyl green-pyronine staining of human skin explant cultures. Toxicol Vitro 16:581
22. Koten JW, Van Luyn MJA, Cadée JA, Brouwer L, Hennink WE, Bijleveld C, Den Otter W (2003) IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy. Cytokine 24:57
23. Krastev Z, Koltchakov V, Popov D, Alexiev A, Koten J-W, Den Otter W (2003) A case of hepatocellular carcinoma (HCC): treatment with local application of alcohol and interleukin 2 (IL-2). Cancer Immunol Immunother 50:1647
24. Krastev Z, Koltchakov V, Vladov N, Popov D, Milev A, Koten JW, Den Otter W (2001) A mesothelioma that is sensitive to locally applied IL-2. Cancer Immunol Immunother 50:226
25. Li J, Gyorffy S, Lee S, Kwok CS (1996) Effect of recombinant human interleukin 2 on neutrophil adherence to endothelial cells in vitro. Inflammation 20:361
26. Locker GJ, Kapiotis S, Veitl M, Mader RM, Stoiser B, Kofler J, Sieder AE, Rainer H, Steger GG, Mannhalter C, Wagner OF (1999) Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disorders. Br J Haematol 105:912
27. Maas RA, Becker MJ, Weimar IS, De Nooy JC, Dullens HFJ, Den Otter W (1993) Transfer of tumour immunity by both CD4+ and CD8+ tumour infiltrating T lymphocytes activated in vivo by IL-2 therapy of tumour bearing mice. Immunobiology 188:281
28. Maas RA, Dullens HFJ, De Jong WH, Den Otter W (1989) Immunotherapy of mice with a large burden of disseminated lymphoma with low-dose interleukin 2. Cancer Res 49:7037
29. Maas RA, Dullens HFJ, Den Otter W (1991) Mechanisms of tumour regression induced by low doses of interleukin-2. In Vivo 5:637
30. Maas RA, Dullens HFJ, Henk D, Van Weering J, De Mik HJ, Koten JW, Belger RJ, Den Otter W (1993) Histological analysis of IL-2 induced regression of murine solid SL2-tumors. Biotherapy 6:83
31. Maas RA, Van Weering DH, Dullens HFJ, Den Otter W (1991) Intratumoral low-dose interleukin-2 induces rejection of distant solid tumour. Cancer Immunol Immunother 33:389
32. - cells correlates with the therapeutic efficacy of lymphoma treatment with IL-2 and/or IL-12. J Immunother 27:107
33. Masztalerz A, Van Rooijen N, Den Otter W, Everse LA (2003) Mechanisms of macrophage cytotoxicity in IL-2 and IL-12 mediated tumour regression. Cancer Immunol Immunother 52:235
34. Moffitt P (1994) A methyl green-pyronin technique for demonstrating cell death in the murine tumour S180. Cell Biol International 18:677
35. Rosenstein M, Ettinghausen SE, Rosenberg SA (1986) Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137:1735
36. Rutten VPMG, Klein WR, De Jong WA, Misdorp W, Den Otter W, Steerenberg PA, De Jong WH, Ruitenberg EJ (1989) Local interleukin-2 therapy in bovine ocular squamous cell carcinoma. A pilot study. Cancer Immunol Immunother 30:165
37. Spoormakers TJP, Klein WR, Jacobs JJL, Van Den Ingh TSGAM, Koten JW, Den Otter W (2003) Comparison of the efficacy of local treatment of equine sarcoids with IL-2 or cisplatin/IL-2. Cancer Immunol Immunother 52:179
38. Ziekman PGPM (1999) Local low-dose IL-2 therapy of tumours in companion animals. Anticancer Res 19:2016
39. Jacobs JJL, Hordijk GJ, Jürgenliemk-Schulz IM, Terhaard CHJ, Koten JW, Battermann JJ, Den Otter W. Treatment of stage III-IV nasopharyngeal carcinomas by external beam irradiation and local low doses of IL-2. Cancer Immunol Immunother 54(in press) (DOI: 10.1007/s00262-004-0641-6)
40. Krastev Z, Koltchakov V, Tomova R, Deredjian S, Alexiev A, Popov D, Tomov B, Bijleveld C, Koten JW, Jacobs JJL, Den Otter W. Locoregional IL-2 therapy in terminal tumour cases presented in our clinic of gastroenterology: intratumoural IL-2 has beneficial effects in 6 out of 7 patients. (Submitted)